TCRT
Alaunos Therapeutics, Inc.Company Information
- Company Name
- Alaunos Therapeutics, Inc.
- CIK
- CIK0001107421
- Category
- Non-accelerated filer<br>Smaller reporting company
- Ticker: Exchange
- TCRT: Nasdaq
- Fiscal Year End
- December 31
- Owner Organization
- 03 Life Sciences
- SIC
- 2834
- SIC Description
- Pharmaceutical Preparations
- Ticker
- TCRT
SEC filing data through
Insider Sentiment
- Last purchase
- 2022-11-29
- Last sale
- 2024-12-31
- Shares purchased (TTM)
- 0
- Shares sold (TTM)
- 3,000
Institutional Sentiment
- As of
- 2026-06-30
- Institutional shares owned
- 90,421
- Shares outstanding
- 2,431,695
- Ownership
- 3.72%
Earnings Market Reaction
- Filing date
- 2026-08-14
- Price on filing date
- —
- 1-month reaction
- -15.54%
- 3-month reaction
- …
Balance Sheet
Values in millions ($)| Line item | 2026-06-30 | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 | 2025-03-31 | 2024-12-31 | 2024-09-30 | 2024-06-30 | 2024-03-31 | 2023-12-31 | 2023-09-30 | Subscriber-only column | Subscriber-only column | Subscriber-only column | Subscriber-only column | Subscriber-only column | Trend |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Assets Current | ||||||||||||||||||
| Cash And Cash Equivalents At Carrying Value | 0 | 0 | 1 | 2 | 3 | 0 | 1 | 2 | 2 | 4 | 6 | 12 | ||||||
| Receivables Net Current | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | ||||||
| Restricted Cash Current | - | - | - | - | - | - | - | - | - | - | 0 | 0 | ||||||
| Prepaid Expense And Other Assets Current | 1 | 1 | 1 | 1 | 1 | 1 | 2 | 2 | 2 | 2 | 2 | 1 | ||||||
| Assets Current | 1 | 1 | 2 | 3 | 4 | 1 | 3 | 4 | 5 | 6 | 8 | 13 | ||||||
| Property Plant And Equipment Net | 0 | 0 | 0 | 0 | - | - | 0 | 0 | 0 | 0 | 0 | 6 | ||||||
| Prepaid Expense And Other Assets Noncurrent | 1 | 1 | 1 | 1 | 1 | 1 | 0 | - | - | - | - | - | ||||||
| Assets | 2 | 2 | 3 | 4 | 5 | 2 | 3 | 4 | 5 | 6 | 8 | 19 | ||||||
| Operating Lease Right Of Use Asset | - | - | - | - | - | - | - | - | - | - | 0 | 1 | ||||||
| Deposits Assets Noncurrent | - | - | - | - | - | - | - | - | - | - | 0 | 0 | ||||||
Liabilities And Stockholders Equity | ||||||||||||||||||
| Other Assets Noncurrent | - | - | - | - | - | - | - | - | - | - | 0 | 0 | ||||||
Liabilities Current | ||||||||||||||||||
| Accounts Payable Current | 1 | 0 | 1 | 1 | 1 | 1 | 1 | 0 | 0 | 1 | 1 | 1 | ||||||
| Accrued Liabilities Current | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 1 | 1 | 3 | ||||||
| Liabilities Current | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 2 | 5 | ||||||
| Liabilities | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 2 | 6 | ||||||
| Long Term Debt Current | - | - | - | - | - | - | - | - | - | - | 0 | 0 | ||||||
Stockholders Equity | ||||||||||||||||||
| Finance Lease Liability Current | - | - | - | - | - | - | - | - | - | - | 0 | 0 | ||||||
| Common Stock Value | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | ||||||
| Additional Paid In Capital Common Stock | 927 | 927 | 927 | 927 | 926 | 923 | 923 | 922 | 922 | 922 | 922 | 922 | ||||||
| Retained Earnings Accumulated Deficit | -927 | -926 | -925 | -924 | -923 | -922 | -920 | -920 | -919 | -917 | -916 | -908 | ||||||
| Finance Lease Liability Noncurrent | - | - | - | - | - | - | - | - | - | - | 0 | 1 | ||||||
| Stockholders Equity | 1 | 1 | 2 | 3 | 4 | 1 | 2 | 3 | 4 | 5 | 6 | 14 | ||||||
| Other Liabilities Noncurrent | - | - | - | - | - | - | - | - | - | - | 0 | 0 | ||||||
| Liabilities And Stockholders Equity | 2 | 2 | 3 | 4 | 5 | 2 | 3 | 4 | 5 | 6 | 8 | 19 | ||||||
| Series A One Preferred Stock | 0 | 0 | 0 | -0 | -0 | 0 | 0 | - | - | - | - | - | ||||||
| Series A Two Preferred Stock | 0 | 0 | 0 | -0 | 0 | - | 0 | - | - | - | - | - | ||||||
| Common Stock Par Or Stated Value Per Share | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | ||||||
| Common Stock Shares Authorized | 50 | 50 | 50 | 50 | 50 | 5 | 50 | 5 | 5 | 35 | 5 | 520 | ||||||
| Common Stock Shares Issued | 2 | 2 | 2 | 2 | 2 | 2 | 2 | 2 | 2 | 16 | 2 | 241 | ||||||
| Shares Outstanding | 2 | 2 | 2 | 2 | 2 | 2 | 2 | 2 | 2 | 16 | 2 | 241 | ||||||
Select a line item above to chart it.
Recent filings
- 10-QFiled
- 10-QFiled
- 10-KFiled
- 10-QFiled
- 10-QFiled
- 10-QFiled
- 10-KFiled
- 10-QFiled
- 10-QFiled
- 10-QFiled
- 10-KFiled
- 10-QFiled
Financial statements beyond 3 years are for subscribers only.
Unlock 17+ years of income statements, balance sheets, and cash flow statements
Start 7-day free trialAlaunos Therapeutics, Inc. (TCRT) — SEC Financial Statements & Analysis
Alaunos Therapeutics, Inc. (TCRT) is a pharmaceutical preparations company, incorporated in DE. Alaunos Therapeutics, Inc. trades on Nasdaq as: TCRT. Alaunos Therapeutics, Inc. (TCRT)'s most recent SEC filing is a Form 10-Q for the period ended 2026-06-30, filed with the SEC on 2026-08-14. Based on that filing, Alaunos Therapeutics, Inc. carries a market cap of $5.50M, a P/E ratio of -1.37x, a P/B ratio of 8.43x, a P/S ratio of 1831.88x, an enterprise value of $5.37M, and an EV/EBITDA multiple of -1.33x. On profitability, it posts an operating margin of -135266.67%, a net margin of -133666.67%, a Return on Equity (ROE) of -185.95%, a Return on Assets (ROA) of -128.30%, and a Return on Invested Capital (ROIC) of -619.45%. Per share, it reports EPS of $-1.65, diluted EPS of $-1.65, free cash flow per share of $-1.16, and a dividend per share of $0.00. Over the trailing year, it posted revenue growth of -57.14% year-over-year, net income growth of 0.45% year-over-year, and EPS growth of -30.75% year-over-year. On the balance sheet, it maintains a current ratio of 0.77x, a quick ratio of 0.14x, working capital of $-198.00K, a debt-to-equity ratio of 1.33x, a debt ratio of 0.57, an interest coverage ratio of -6.25x, free cash flow of $-2.83M (TTM), and net debt of $-124.00K. Figures sourced from SEC EDGAR.
- Market Cap
- $5.50M
- P/E TTM
- -1.37x
- EPS TTM
- $-1.65
- P/B TTM
- 8.43x
- ROE TTM
- -185.95%
- ROA TTM
- -128.30%
- Debt To Equity
- 1.33x
- Free Cash Flow TTM
- $-2.83M
- Net Revenue TTM Growth 1Y
- -57.14%
Data as of 2026-06-30 · Source: SEC EDGAR
Frequently Asked Questions
What industry is Alaunos Therapeutics, Inc. in?
Alaunos Therapeutics, Inc. (TCRT) operates in the Pharmaceutical Preparations industry.
What exchange does TCRT trade on?
Alaunos Therapeutics, Inc. (TCRT) trades on the Nasdaq.
Where is Alaunos Therapeutics, Inc. incorporated?
Alaunos Therapeutics, Inc. is incorporated in DE.
When was Alaunos Therapeutics, Inc. (TCRT)'s most recent SEC filing?
Alaunos Therapeutics, Inc. (TCRT)'s most recent SEC filing is a Form 10-Q for the period ended 2026-06-30, filed with the SEC on 2026-08-14.
What is TCRT's market cap?
Alaunos Therapeutics, Inc. (TCRT) has a market capitalization of $5.50M as of 2026-06-30.
What is TCRT's EPS (earnings per share)?
Alaunos Therapeutics, Inc. (TCRT)'s trailing twelve month EPS is $-1.65 as of 2026-06-30.
What is TCRT's ROE (return on equity)?
Alaunos Therapeutics, Inc. (TCRT)'s trailing twelve month Return on Equity (ROE) is -185.95% as of 2026-06-30.
What is TCRT's ROA (return on assets)?
Alaunos Therapeutics, Inc. (TCRT)'s trailing twelve month Return on Assets (ROA) is -128.30% as of 2026-06-30.
What is TCRT's ROIC (return on invested capital)?
Alaunos Therapeutics, Inc. (TCRT)'s trailing twelve month Return on Invested Capital (ROIC) is -619.45% as of 2026-06-30.
What is TCRT's EV/EBITDA?
Alaunos Therapeutics, Inc. (TCRT)'s trailing twelve month EV/EBITDA is -1.33x as of 2026-06-30.